What is immunotherapy and does it work for HER2-Positive Breast Cancer

Understanding Immunotherapy and HER2-Positive Breast Cancer

What Is Immunotherapy?

Immunotherapy is a type of cancer treatment that works differently than traditional chemotherapy. Instead of directly poisoning cancer cells, immunotherapy trains and activates your own immune system to recognize and attack cancer cells.

Think of it this way: Your immune system evolved to fight infections like bacteria and viruses. But cancer cells are clever—they hide from your immune system by disguising themselves as "normal self" cells. Immunotherapy essentially teaches your immune cells (particularly T cells, which are killer immune cells) to unmask the cancer and destroy it.

According to the Society of Immunotherapy of Cancer (SITC) educational resources, there are several types of immunotherapy approaches:

• Checkpoint inhibitors: These "release the brakes" on immune cells that have been shut down by cancer. Drugs like Keytruda (pembrolizumab) work this way.
• Cancer vaccines: These personalized vaccines train your immune system to recognize specific mutations unique to YOUR tumor
• CAR-T cell therapy: Your own immune cells are removed, engineered in a lab to better recognize cancer, and returned to your body
• Monoclonal antibodies: Man-made proteins that target specific molecules on cancer cells

---

Does Immunotherapy Work for HER2-Positive Breast Cancer?

This is an important question, and the honest answer is: it's complicated for HER2-positive breast cancer specifically.

The Current Reality

HER2-positive breast cancer is considered a "hot" tumor for targeted therapy (meaning it responds well to drugs that directly target the HER2 protein), but it has historically been a "cold" tumor" for immunotherapy (meaning it doesn't respond as well to checkpoint inhibitors alone).

According to clinical research discussed in CancerPatientLab webinars on immunotherapy approaches:

• Standard checkpoint inhibitors alone have NOT shown strong responses in HER2-positive breast cancer
• There are no FDA-approved immunotherapy regimens specifically for HER2-positive breast cancer as a standalone treatment
• However, combination approaches are showing promise

What IS Working: Combination Strategies

The most exciting developments involve combining immunotherapy with HER2-targeted drugs:

HER2-Targeted Antibody-Drug Conjugates (ADCs): Recent advances include drugs like trastuzumab deruxtecan (Enhertu), which combines:

• An anti-HER2 antibody (trastuzumab—the same drug used in traditional HER2 therapy)
• A chemotherapy payload delivered directly to HER2-positive cells

According to proteomics research presented in clinical guidance webinars, when HER2 protein levels are very high (over-expressing), patients treated with dual anti-HER2 therapies or ADCs have shown "vast improvement in their outcomes."

Combination with Checkpoint Inhibitors: Researchers are actively studying combinations of:

• HER2-targeted drugs + checkpoint inhibitors
• Personalized cancer vaccines + checkpoint inhibitors + HER2-targeted therapy

One notable example from clinical case reports involved a pancreatic cancer patient with HER2 expression who received a personalized vaccine combined with checkpoint inhibitors and later an HER2 antibody-drug conjugate, resulting in sustained disease control.

---

Key Questions to Ask Your Oncologist

Since HER2-positive breast cancer treatment is evolving, here are specific questions to discuss with your care team:

1. "What is my specific HER2 expression level, and does that affect which immunotherapy approaches might work for me?"

2. "Are there clinical trials combining HER2-targeted drugs with immunotherapy that I might be eligible for?"

3. "Would a personalized cancer vaccine combined with my standard HER2 therapy be appropriate for my situation?"

4. "If I progress on standard HER2 therapy, what immunotherapy combinations would you consider next?"

5. "Are there tests (like PD-L1 or tumor mutational burden) that could help predict if immunotherapy would work in my case?"

---

The Bottom Line

For HER2-positive breast cancer:

• ✅ HER2-targeted drugs (like trastuzumab/Herceptin) remain the standard of care and are highly effective
• ✅ Newer antibody-drug conjugates (like Enhertu) are expanding options, especially for advanced disease
• ⏳ Immunotherapy alone is NOT yet standard, but combination approaches are being actively researched
• ⏳ Clinical trials may offer access to promising combination strategies

Your oncologist will determine the most appropriate approach based on your specific situation, including your disease stage, prior treatments, and individual tumor characteristics.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.